drugset
drugset / Trial / NCT02680951

Dasatinib in Combination With Chemotherapy for Relapsed or Refractory Core Binding Factor Acute Myeloid Leukemia

NCT02680951 ↗

Phase 1 Withdrawn Emory University
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will examine the appropriate dose and side effects of dasatinib, when it is given with the standard of care chemotherapy for children and adolescents with Acute Myeloid Leukemia (AML).

Timeline

Start
2015-12
Primary completion
2017-12-15
Completion
2017-12-15

Drugs

EvaluationDrugModalityDoseRoute
Subject dasatinib anhydrous Small molecule 60 mg/m2 Oral
Subject dasatinib anhydrous Small molecule 80 mg/m2 Oral
Subject dasatinib anhydrous Small molecule 100 mg/m2 Oral
Background Cytarabine Small molecule 30 mg Intravenous
Background Cytarabine Small molecule 50 mg Intravenous
Background Cytarabine Small molecule 70 mg Intravenous
Background Cytarabine Small molecule 2000 mg/m2 Intravenous
Background Fludarabine Small molecule 30 mg/m2 Intravenous
Background Idarubicin Small molecule 8 mg/m2 Intravenous

Indications

acute myeloid leukemia